Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia

被引：14
|
作者：
Zhang, Keyuan [1 ]
Zhang, Xiang [1 ]
Xu, Yang [1 ,2 ,3 ]
Xue, Shengli [1 ,2 ]
Qiu, Huiying [1 ,2 ]
Tang, Xiaowen [1 ,2 ,3 ]
Han, Yue [1 ,2 ,3 ]
Chen, Suning [1 ,2 ,3 ]
Sun, Aining [1 ,2 ]
Zhang, Yanming [4 ,5 ]
Wu, Depei [1 ,2 ,3 ,6 ]
Wang, Ying [1 ,2 ,3 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
[3] Minist Hlth, Key Lab Thrombosis & Hemostasis, Suzhou, Peoples R China
[4] Xuzhou Med Univ, Affiliated Huaian Hosp, Dept Hematol, Dept Neurosurg, 62 Huaihai Rd S, Huaian, Peoples R China
[5] Second Peoples Hosp Huaian, 62 Huaihai Rd S, Huaian, Peoples R China
[6] Soochow Univ, State Key Lab Radiat Med & Protect, Suzhou, Peoples R China
来源：
BLOOD CANCER JOURNAL | 2023年 / 13卷 / 01期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1038/s41408-023-00928-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
    Bataller, Alex
    Bazinet, Alexandre
    Dinardo, Courtney D.
    Maiti, Abhishek
    Borthakur, Gautam
    Daver, Naval G.
    Short, Nicholas J.
    Jabbour, Elias J.
    Issa, Ghayas C.
    Pemmaraju, Naveen
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    Takahashi, Koichi
    Loghavi, Sanam
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD ADVANCES, 2024, 8 (04) : 927 - 935
  • [32] Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
    Morsia, Erika
    McCullough, Kristen
    Joshi, Maansi
    Cook, Joselle
    Alkhateeb, Hassan B.
    Al-Kali, Aref
    Begna, Kebede
    Elliott, Michelle
    Hogan, William
    Litzow, Mark
    Shah, Mithun
    Pardanani, Animesh
    Patnaik, Mrinal
    Tefferi, Ayalew
    Gangat, Naseema
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1511 - 1521
  • [33] Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents
    Johnson, Isla M.
    Bezerra, Evandro D.
    Farrukh, Faiqa
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Patnaik, Mrinal M.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2021, 138
  • [34] Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
    Liu, Fangtong
    Wan, Chao-Ling
    Liu, Yu-Qing
    Huang, Yuan-Hong
    Cao, Han-Yu
    Huang, Si-Man
    Tan, Kai-Wen
    Ge, Shuai-Shuai
    Wang, Miao
    Liu, Mei-Jing
    Wang, Zihao
    Xue, Sheng-Li
    Dai, Haiping
    BLOOD, 2024, 144 : 1484 - 1485
  • [35] Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
    Jin, Dian
    He, Jingsong
    Chen, Haoguang
    Wu, Wenjun
    Han, Xiaoyan
    Le, Jing
    Shu, Wenxiu
    Yang, Qianqian
    Pei, Shanshan
    Cai, Zhen
    He, Donghua
    CANCER MEDICINE, 2024, 13 (14):
  • [36] Exposure-Response Analysis of Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
    Agarwal, Suresh
    Gopalakrishnan, Sathej
    Mensing, Sven
    Potluri, Jalaja
    Hayslip, John
    Friedel, Anna
    Menon, Rajeev
    Salem, Ahmed Hamed
    BLOOD, 2018, 132
  • [37] Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States
    Vachhani, Pankit
    Abbas, Jonathan A.
    Flahavan, Evelyn M.
    Ma, Esprit
    Xu, Tao
    Jin, Huan
    Montez, Melissa
    Huang, Weize
    Gershon, Anda
    Ku, Grace
    Flores, Brannon
    Onishi, Maika
    Bui, Cat N.
    Donnellan, William
    BLOOD, 2021, 138
  • [38] Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)
    Ball, Brian J.
    Arslan, Shukaib
    Koller, Paul
    Ngo, Dat
    Afkhami, Michelle
    Salhotra, Amandeep
    Al-Malki, Monzr
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Otoukesh, Salman
    Amanam, Idoroenyi
    Pourhassan, Hoda
    Artz, Andrew
    Curtin, Peter
    Stein, Anthony
    Nakamura, Ryotaro
    Marcucci, Guido
    Smith, Eileen
    Pullarkat, Vinod
    Aldoss, Ibrahim
    LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3232 - 3236
  • [39] Fusion Transcript Reduction in Core Binding Factor Acute Myeloid Leukemia: Maintenance Strategy with Hypomethylating Agents
    Ragon, Brittany Knick
    Daver, Naval
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Ferrajoli, Alessandra
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Borthakur, Gautam
    BLOOD, 2015, 126 (23)
  • [40] Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients
    Yu, Hong
    Wang, Chaomeng
    Lei, Yingying
    Li, Lijuan
    Wang, Huaquan
    Wang, Guojin
    Xing, Limin
    Guan, Jing
    Song, Jia
    Wu, Yuhong
    Liu, Hong
    Qu, Wen
    Wang, Xiaoming
    Shao, Zonghong
    Fu, Rong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
12345